Humanigen Data Show Success In High-Risk COVID-19 Population
Lenzilumab Heads To FDA
Phase III results show benefit in cytokine-release syndrome, while other drugs for treating patients hospitalized with COVID-19 have produced mixed results.
You may also be interested in...
Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
Drugs for ARDS in COVID-19 have yielded mixed results in the clinic, with Boehringer Ingelheim pulling one from Phase II development earlier this month.